相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han et al.
NEURO-ONCOLOGY (2014)
Progression-free survival: too much risk, not enough reward?
Brian M. Alexander et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification
Parvin Tajik et al.
CLINICAL CANCER RESEARCH (2013)
Adaptive Randomization Versus Interim Monitoring Reply
Lorenzo Trippa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adaptive Randomization Versus Interim Monitoring
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio Omuro et al.
NEURO-ONCOLOGY (2013)
Biomarker-based adaptive trials for patients With glioblastoma-lessons from I-SPY 2
Brian M. Alexander et al.
NEURO-ONCOLOGY (2013)
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
Paul A. Northcott et al.
ACTA NEUROPATHOLOGICA (2012)
Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma
Lorenzo Trippa et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
Evanthia Galanis et al.
LANCET ONCOLOGY (2012)
Adaptive clinical trials in oncology
Donald A. Berry
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues
Justin M. Craig et al.
PLOS ONE (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
Role of isocitrate dehydrogenase in glioma
Brian M. Alexander et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Adaptive Clinical Trials: The Promise and the Caution
Donald A. Berry
JOURNAL OF CLINICAL ONCOLOGY (2011)
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Zachary J. Reitman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Recurrent High-Grade Glioma
Eudocia C. Quant et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2010)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
Mei-Yin C. Polley et al.
NEURO-ONCOLOGY (2010)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
